Story perspectives

Viloxazine ER Shows Promise for Pediatric ADHD Treatment

1/27/2026

33 4

Summary

Story summary

Viloxazine ER demonstrated tolerability similar to ADHD medications in a pediatric trial, with 7.6% discontinuations due to adverse events.
The trial overlapped the COVID-19 pandemic and reported low adverse events, mostly mild.
Suicidal ideation occurred in 2.2% of participants, lower than Centers for Disease Control and Prevention rates.
Excluding psychiatric comorbidities may bias results, but viloxazine ER shows efficacy and safety and warrants further studies in children with ADHD.

1 of 1

Story summary

Viloxazine ER demonstrated tolerability similar to ADHD medications in a pediatric trial, with 7.6% discontinuations due to adverse events.
The trial overlapped the COVID-19 pandemic and reported low adverse events, mostly mild.
Suicidal ideation occurred in 2.2% of participants, lower than Centers for Disease Control and Prevention rates.
Excluding psychiatric comorbidities may bias results, but viloxazine ER shows efficacy and safety and warrants further studies in children with ADHD.